Loading
A phase 2 trial of Rilvegostomig, CAPOX (capecitabine, oxaliplatin) and Capecitabine in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma is a phase 2 interventional study registered as NCT05702229 by AstraZeneca, with 163 participants planned, started 2023-01-16 and due to reach its primary completion in 2027-11-30. Interventions recorded: Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901 and 5-Fluorouracil.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares CAPOX (capecitabine, oxaliplatin), Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/